FindMyKOL

Sameer Parikh, MD

Enriched profile

Associate Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic Rochester · Mayo Clinic in Rochester

ORCID↗NPI↗
✓ Itemized profile
Region🇺🇸 Rochester, MN · Midwest · United StatesSpecialtyHematologyFocusChronic Lymphocytic Leukemia Research+4
Active KOLFindMyKOL type: EliteLatest publication2026Online presenceNone verifiedPayments2021–2025NIH funding2024–2026

Sameer Parikh is Associate Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic Rochester at Mayo Clinic in Rochester. OpenAlex indexes 467 publications with 8,981 citations (h-index 47); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.

Data verified 19 Oct 2026

Overview

Updated 28 Oct 2026

Sameer Parikh, M.D., is Associate Professor of Medicine and Consultant, Division of Hematology, Mayo Clinic Rochester at Mayo Clinic in Rochester, Minnesota. The public record shows 467 publications with 8,981 citations (h-index 47), centered on Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Acute Lymphoblastic Leukemia research. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 11 companies, 1 NIH-funded awards (2024–2026).

  • Most recent indexed publication: 2026 · Blood cancer journal
  • Top research focus: Chronic Lymphocytic Leukemia Research
  • 5 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 11 companies

Generated from the cited public record · current as of 28 Oct 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Leukemia (AML/ALL/CML/CLL)4 trialsLymphoma3 trialsLeukemia, Lymphocytic, Chronic, B-Cell3 trialsLeukemia, Lymphoid3 trialsLymphocytosis2 trialsHodgkin Disease1 trialViral Hepatitis (B/C)1 trialHepatitis C1 trialCOVID-191 trialWaldenstrom Macroglobulinemia1 trial

Research focus

OpenAlex concept fingerprint
Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and TreatmentAcute Lymphoblastic Leukemia researchCAR-T cell therapy researchAcute Myeloid Leukemia Research

Drugs & molecules

across trials, industry payments and publications
Venclextageneric · VenetoclaxClinical trials—Industry payments19Publications6Imbruvicageneric · IbrutinibClinical trials—Industry payments7Publications15Epkinlygeneric · EpcoritamabClinical trials—Industry payments8Publications—Calquencegeneric · AcalabrutinibClinical trials—Industry payments6Publications—Gamifantgeneric · EmapalumabClinical trials—Industry payments1Publications—Tecartusgeneric · Brexucabtagene autoleucelClinical trials—Industry payments1Publications—UmbralisibClinical trials—Industry payments1Publications—Xgevageneric · DenosumabClinical trials—Industry payments1Publications—

Works with

trial sponsors and companies reporting payments
Abbvie Inc.Clinical trials—Industry payments28Merck Sharp & Dohme LLCClinical trials—Industry payments11AstraZeneca Pharmaceuticals LPClinical trials—Industry payments8Janssen Global Services, LLCClinical trials—Industry payments7Genentech USA, Inc.Clinical trials—Industry payments3Mayo ClinicClinical trials3Industry payments—Academic and Community Cancer Research UnitedClinical trials1Industry payments—Amgen Inc.Clinical trials—Industry payments1Genentech, Inc.Clinical trials—Industry payments1Gilead Sciences, Inc.Clinical trials—Industry payments1Ohio State University Comprehensive Cancer CenterClinical trials1Industry payments—Sobi, IncClinical trials—Industry payments1Tg Therapeutics, Inc.Clinical trials—Industry payments1

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
467publications

Distinct works indexed by OpenAlex, matched via ORCID; 77 in PubMed.

8,981citations

Total citations across indexed works.

47h-index

Hirsch index (OpenAlex). i10-index 130.

Clinical & industry

trials, payments and federal funding
5clinical trials

Investigator role on registered studies.

View trials ↓
11companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2024–2026

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 28 Oct 2026

Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:

All 5 trial records: search, sort and filter.Explore →

Industry payments

Updated 28 Oct 2026

11 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

All 23 payment records: search, sort and filter.Explore →
View the CMS Open Payments record ↗

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    90.7%
    SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor54.6%
    Remdesivir100%
    Part B, office-administered≥12 patients
    Human Immunoglobulin G35.6%
    Immune globulin100%
    Part B, office-administered≥14 patients

    + 1 more class in this area

  • Cancer & immunology

    7.2%
    Kinase inhibitor5.1%
    Imbruvica42%Calquence32%Brukinsa14%Jaypirca12%
    Part D<11 patients
    BCL-2 Inhibitor2.1%
    Venclexta100%
    Part D<11 patients

  • Dermatology

    1.7%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor1.7%
    Acyclovir100%
    Part D≥20 patients
All 4 therapeutic areas: search, sort and filter.Explore →
Where care is delivered (Part B)3.8% facility · 96.2% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

Updated 28 Oct 2026

1 NIH research award on record, funded 2024–2026 per NIH RePORTER. The latest:

Congress activity

Updated 28 Oct 2026

135 congress contributions (2010–2026) across AACR, ASCO, ASH, ESMO per OpenAlex. The most recent:

All 135 congress records: search, sort and filter.Explore →

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 28 Oct 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

All 77 publications: search, sort and filter.Explore →

Most-cited works

by citation count (OpenAlex)
  1. 01
    Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL
    Article962 citations2018
    doi.org ↗
  2. 02
    Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
    Article534 citations2015
    doi.org ↗
  3. 03
    Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
    Article407 citations2017
    doi.org ↗
  4. 04
    Prognostic Factors and Outcomes of Adults With Hemophagocytic Lymphohistiocytosis
    Article324 citations2014
    doi.org ↗
  5. 05
    Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
    Article289 citations2016
    doi.org ↗
All 467 cited works: search, sort and filter.Explore →

Network

Updated 28 Oct 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Neil E. Kay303Timothy G. Call183Susan L. Slager173Saad S. Kenderian165Wei Ding159Kari G. Rabe158Tait D. Shanafelt120Jose Francisco Leis110Esteban Braggio104Paul Joseph Hampel96Yucai Wang85Reona Leo Sakemura81Curtis A. Hanson80Mehrdad Hefazi77Susan Marie Schwager75Michelle J. Cox72Kendall J. Schick72Sutapa Sinha70Michael W. Ruff68Eli Muchtar68Claudia Manriquez Roman68Amber B. Koehler66Elizabeth L. Siegler65Erin E. Tapper65İsmail Can63Lionel Aurelien Kankeu Fonkoua62James R. Cerhan62Paulina Horvei59Evandro D. Bezerra58Mohamad M. Adada58Justin C. Boysen53Sara J. Achenbach49Carli M. Stewart48Wendy Kay Nevala48Michael J. Hansen47Min Shi47Daniel L. Van Dyke46Aaron D. Norman40Steven L. Warner40Renee C. Tschumper39

Online presence

Updated 28 Oct 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • Other

    lls.org/award-recipient/sameer-parikh

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →lls.org ↗
  • Other

    cllsociety.org

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cllsociety.org ↗
  • Other

    healthtree.org/cll/directory/mn/mayo-clinic-rochester-rochester-mn/sameer-parikh

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • Other

    cancercommons.org/authors/sameer-a-parikh-mbbsc

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercommons.org ↗
  • Other

    mayo.edu/research/faculty/parikh-sameer-a-m-b-b-s/bio-20396891

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayo.edu ↗
  • Other

    mayoclinic.org/biographies/parikh-sameer-a-mbbs/bio-20096684

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →mayoclinic.org ↗

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 28 Oct 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • CLL Abstract Review Committee Member

    American Society of Hematology Annual Meeting

    2020
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • CLL Abstract Coordinating Reviewer

    American Society of Hematology Annual Meeting

    2018
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • Core Leukemia Committee Member

    ECOG-ACRIN

    2018
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • CLL Abstract Reviewer

    American Society of Hematology Annual Meeting

    2017
    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • Chair

    CLL Disease Team, Mayo Clinic Comprehensive Cancer Center

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
  • Member

    American Society of Hematology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
  • Chair

    CLL Disease Team

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
  • Abstract Review Committee Member

    American Society of Hematology

    provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthtree.org ↗
  • Member

    American Society of Clinical Oncology

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗
  • Member

    Eastern Cooperative Oncology Group-ACRIN

    verifiedCorroborated by FindMyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →healthtree.org ↗

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution

Media & interviews

press, podcasts and appearances

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.